|
|
Combivir (AZT/3TC)
| Brand Name: |
Combivir |
| Generic Name: |
Zidovudine and lamivudine, AZT and 3TC |
| Adult Single Dose: |
One tablet containing 300 mg AZT and 150 mg 3TC
(twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Combivir (AZT/3TC) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Combivir (Zidovudine/Lamivudine, AZT/3TC) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Combivir (Zidovudine + Lamivudine) (November 7, 2007)
To read PDF, click here
From AIDS InfoNet
- Combivir (AZT + Epivir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Combivir (AZT/3TC) (PDF) (March 2007)
From GlaxoSmithKline
- Combivir (AZT/3TC) (October 19, 2006)
From AIDS Treatment Data Network
- Drug Interactions: Combivir (August 2004)
From Project Inform
- GlaxoSmithKline Alerts Patients, Pharmacists and Physicians to Watch for Third-Party Tampering That Incorrectly Labels Ziagen as Combivir (May 10, 2002)
From U.S. Food and Drug Administration
- FDA Approves First Combination Drug for AIDS (September 29, 1997)
Combivir (combination of zidovudine and lamivudine) receives traditional approval for treating AIDS and HIV infection.
From U.S. Food and Drug Administration
News
Research
- Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Zidovudine/Lamivudine Inferior as First-Line NRTI Backbone (August 15, 2006)
In XVI International AIDS Conference
- In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Aurobindo Receives Tentative FDA Approval to Produce Generic Version of Combivir for PEPFAR (July 11, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Aurobindo Pharma Receives Tentative FDA Approval to Produce Generic Stavudine for PEPFAR (July 5, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
In The XV International AIDS Conference, from The Body PRO
- U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here
From U.S. National Institute of Allergy and Infectious Diseases
- Adherence to Combivir as Post-Exposure Prophylaxis in Non-Occupational HIV Exposures (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Metabolic and Anthropometric Changes Observed in HIV-Infected Patients Treated With Combivir (ZDV/3TC) Plus Nelfinavir or Nevirapine (A Substudy of the COMBINE Study) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Final 12-Month Results From the COMBINE Study: A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in Naive Patients (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The PI-Sparing Compact Quad Regimen of Combivir (COM)/Abacavir (ABC)/Efavirenz (EFV) Is Potent and Well-Tolerated in Antiretroviral Therapy (ART) Naive Subjects With High Viral Loads: 24-Wk Data (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efficacy of Combivir (COM) (Lamivudine 150 mg/Zidovudine 300 mg) Plus Ziagen (Abacavir (ABC) 300 mg) BID Compared to Trizivir (TZV) (3TC 150 mg/ZDV 300 mg/ABC 300 mg) BID in Patients Receiving Prior COM Plus ABC (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- NZT4002: 64-week Analysis of Combivir (COM)-Based Triple and Quadruple Therapy in Antiretroviral-Naive, HIV-1-Infected Subjects (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Studies Suggest AZT/3TC/Abacavir May Offer Adequate Potency (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
|
|
